India's Dr Reddy's to manufacture Biosignal's furanones

By Renate Krelle
Thursday, 20 January, 2005

Sydney-based Biosignal (ASX:BOS) has engaged Custom Pharmaceutical Serivces, a business unit of Indian generics-manufacturing specialist Dr Reddy's Laboratories, to develop a large-scale manufacturing procedure for Biosignal's antibacterial furanone compounds.

Dr Reddy's will then synthesise furanones for use in product development and registration Biosignal's anti-bacterial contact lenses and antifouling paints.

Custom Pharmaceutical Serivces produces cGMP compliant products in ISO certified facilities. Hyderabad-based Dr Reddy's is listed on the NYSE, and is best known for its aggressive pursuit of the generics market, launching numerous patent challenges against big pharma drugs. Its marketing rights for a generic version of Eli Lilly's Prozac ended two years ago. Dr Reddy's is also conducting research into new drugs.

Related News

Vanillin flavouring in vapes may disrupt embryo development

Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...

Heart valve tissues created from stem cells

The breakthrough should help advance our understanding into how human heart valves develop,...

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd